Last term, the Supreme Court concluded that an order requiring the production of privileged materials cannot typically be appealed as a final judgment under the rule of Cohen v. Beneficial Indus. Loan Corp., 337 U.S. 541 (1949). Mohawk Industries, Inc. v. Carpenter, 130 S.Ct. 599 (2009). Cohen is the predicate for the so-called collateral order doctrine. Under that doctrine, an order may be viewed as final for purposes of appeal under 28 U.S.C. § 1291 if it is collateral to the litigation and fully resolves an issue. In Mohawk Industries, the Court rejected claims that an order requiring the production of privileged materials comes within the limited exception provided by Cohen and its progeny. The Court reasoned that review at the conclusion of the litigation would be sufficient. The Court buttressed its conclusion by noting that there may be other avenues of review such as non-compliance and appealing the resulting order of contempt.

In U.S. v. Krane, No. 10-30247 (9th Cir. Oct. 29, 2010), the Ninth Circuit concluded that Mohawk Industries does not foreclose the use of the Perlman exception. In Krane, an appeal was taken by intervenor Quellos Group LLC from an order directing the law firm of Skadden Arps to produce certain privileged materials. Skadden was former counsel to Quellos. The government issued a pre-trial subpoena to the law firm in anticipation of the criminal trial of two former Quellos executives. The defendants were accused of creating a fraudulent tax shelter. Key to the sale of that tax shelter was opinions from reputable law firms attesting to the fact that it was more likely than not that the tax shelter would survive IRS scrutiny.

When the district court authorized the issuance of the subpoena, the company informed Skadden that it was asserting attorney client privilege. The firm did not produce the documents. When the government to compel, Quellos requested and obtained leave to intervene. The company opposed the motion.

Subsequently, the defendants entered into plea agreements. Nevertheless, the government issued a second, identical subpoena, arguing the materials were necessary for sentencing. Quellos filed a suggestion of mootness, which was opposed by the government. The motion to compel was granted.

On appeal, the Ninth Circuit concluded that it properly had jurisdiction. Under Section 1291 of Title 28, appeals may only be taken from final judgments, the Court began. Typically, an order compelling compliance with a subpoena can only be appealed from a resulting contempt citation. Although Skadden has not been held in contempt under Perlman v. U.S., 247 U.S. 7 (1918), the appeal here is proper. Under Perlman, a discovery order requiring the production of privileged materials from a third party is immediately appealable. This is because the third party does not have a sufficient interest in the proceeding and most likely would produce the documents, rather than challenge the order by submitting to a contempt citation.

Here, Skadden is a disinterested third party because it is now the former counsel of Quellos. In contrast, if Skadden continued to be counsel to Quellos, it would be deemed an interested party, the Court held, and the Perlman rule would not apply.

Finally, it is clear that Perlman survives Mohawk Industries, the Circuit Court stated. The latter “forecloses interlocutory appeal of some district court orders in reliance on the fact that post judgment appeals generally suffice to protect the rights of litigants and assure the vitality of the attorney-client privilege;” quoting Mohawk Industries. This is not the case under the Perlman rule, because it only applies to third parties who would have no interest in appealing the ruling.

Ultimately the Court adopted the suggestion of mootness. The appeal was dismissed as moot and the district court’s order compelling compliance was vacated. The case was remanded to the district court.

The criminalization of securities enforcement has increased in recent years. In many instances, it is difficult if not impossible to discern the dividing line between criminal and civil securities actions (here). The virtual demise of the formal criminal reference process at the SEC in favor of coordination with various law enforcement agencies through the President’s task force (here) and the Virginia task force (here) have contributed to this trend and perhaps caused its acceleration.

In many instances, this results in coordinated filings such as when the SEC and the U.S. Attorney’s Office jointly announced the first option backdating cases (here). These trends continue with the filing of civil and criminal insider trading charges against a French national, Dr. Yves Benhamou. SEC v. Benhamou, Civil Action No. 10-CV-8266 (S.D.N.Y. Filed Nov. 2, 2010) and U.S. v. Benhamou (S.D.N.Y. Filed Nov. 1, 2010).

The charges against Dr. Benhamou stem from two of his professional positions. One is on the five member steering committee of biopharmaceutical company Human Genome Sciences, Inc. (“HGSI”) of Rockville, Maryland. The other is as a consultant to the portfolio manager and investment advisors to a group of hedge funds that buy and sell healthcare related securities.

Dr. Benhamou, a medical doctor residing in France, specializes in hepatitis and other diseases of the liver. He is the Chief of Department, Clinical Research in Hepatology, Hôpitaux de Paris-Pitié-Salpétrière and an Associate Professor of Hepatology at the Hôpitaux de Paris-Salpétrière in Paris, France. He is also a clinical investigative physician for HGSI and was involved the clinical trials for Albuferon, a new drug to treat liver disease Hepatitis C.

The Phase 3 late-stage development clinical trial to test safety and efficiency of the drug began in August 2007. Phase 2 testing had been successful. Throughout the Phase 3 trial the company confirmed the findings of Phase 2. It also publically stated that Albuferon could become the “interferon of choice” for the treatment of hepatitis C. HGSI believed that the drug had tremendous commercial potential.

From February 2007 through early December of that year, six hedge funds (collectively referred to in the complaint as “Healthcare Funds), each of which had a separate investment adviser and had co-portfolio managers (designated in the complaint as Nos. 1-6) employed at an investment bank (in the complaint collectively referred to as “Healthcare Fund Advisors”), purchased about 6.2 million shares of HGSI at an average price of $10.32 per share. Dr. Benhamou was an advisor to the co-portfolio mangers of the Healthcare Funds.

Beginning in November 2007, serious adverse events were reported in connection with the Albuferon trials. Specifically, one patient in the test died while another was hospitalized. Ultimately, on January 23, 2008, HGSI issued a press release concerning the trials noting that at one dosage level they were discontinued. Following the issuance of this press release, the share price dropped from $10.02 to $5.62.

Between the reporting of the first serious adverse event and the issuance of the January 23 press release, there were a series of internal meetings and discussions assessing the available information about the drug trials and whether they should proceed. Dr. Benhamou was kept apprised of the evolving situation. As he was updated, Dr. Benhamou kept Co-Portfolio Manager 1 informed, according to the complaint. For example, after the initial incident report in November 2007, and before any decision was made on how to proceed, Dr. Benhamou is alleged to have furnished the negative information to Co-Portfolio Manager I. As a result, the Healthcare Fund Advisors caused the Healthcare Funds to sell a small portion of their holdings.

This pattern repeated over the time period leading up to the public announcement that the trials at one dosage level would be discontinued. By the time of that announcement the Healthcare Funds had sold their position, avoiding at least a $30 million loss. Nevertheless, following the public announcement Co-Portfolio Manager 1 told the other portfolio managers, he still wanted to own HGSI stock. Accordingly he made a buy recommendation at $6 per share. The Healthcare Funds then purchase about 2.4 million shares. The co-portfolio managers maintained that the stock was undervalued. They had a target price of $17 per share through at least April 2008.

The SEC’s complaint alleges violations of Securities Act Section 17(a) and Exchange Act Section 10(b). See also Litig. Rel. 21721 (Nov. 2, 2010). The criminal complaint contains one count of conspiracy to commit securities fraud and one count of securities fraud. Both cases are in litigation.